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Abstract
Background: Infectious disease is often the reason for intravenous drug users being seen in a
clinical setting. The objective of this study was to evaluate the appropriateness of treatment and
outcomes for this patient population in a hospital setting.
Methods:  Retrospective study of all intravenous drug users hospitalized for treatment of
infectious diseases and seen by infectious diseases specialists 1/2001–12/2006 at a university
hospital. Treatment was administered according to guidelines when possible or to alternative
treatment program in case of patients for whom adherence to standard protocols was not possible.
Outcomes were defined with respect to appropriateness of treatment, hospital readmission,
relapse and mortality rates. For statistical analysis adjustment for multiple hospitalizations of
individual patients was made by using a generalized estimating equation.
Results:  The total number of hospitalizations for infectious diseases was 344 among 216
intravenous drug users. Skin and soft tissue infections (n = 129, 37.5% of hospitalizations),
pneumonia (n = 75, 21.8%) and endocarditis (n = 54, 15.7%) were most prevalent. Multiple
infections were present in 25%. Treatment was according to standard guidelines for 78.5%,
according to an alternative recommended program for 11.3%, and not according to guidelines or
by the infectious diseases specialist advice for 10.2% of hospitalizations. Psychiatric disorders had a
significant negative impact on compliance (compliance problems in 19.8% of hospitalizations) in
multiple logistic regression analysis (OR = 2.4, CI 1.1–5.1, p = 0.03). The overall readmission rate
and relapse rate within 30 days was 13.7% and 3.8%, respectively. Both non-compliant patient
behavior (OR = 3.7, CI 1.3–10.8, p = 0.02) and non-adherence to treatment guidelines (OR = 3.3,
CI 1.1–9.7, p = 0.03) were associated with a significant increase in the relapse rate in univariate
analysis. In 590 person-years of follow-up, 24.6% of the patients died: 6.4% died during
hospitalization (1.2% infection-related) and 13.6% of patients died after discharge.
Conclusion:  Appropriate antibiotic therapy according to standard guidelines in hospitalized
intravenous drug users is generally practicable and successful. In a minority alternative treatments
may be indicated, although associated with a higher risk of relapse.
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Background
Infectious diseases are a major cause of morbidity and
mortality among intravenous drug users (IVDU) [1-8].
Malnutrition, immunodeficiency, homelessness, and nee-
dle-sharing contribute to a high infection rate in these
patients [7,9]. Thus, reducing these risk factors and pro-
viding adequate medical care are important aims of opi-
oid maintenance programs [10,11]. In general, IVDU seek
medical treatment in emergency departments more often
and also need to be hospitalized more often than patients
in an age-matched non-IVDU population [4,10]. They
also tend to seek medical attention late in the course of a
disease [4]. The resulting delay in diagnosis and possibly
reduced number of available therapeutic options may
produce a less favorable outcome to treatment as well as
more frequent and potentially life-threatening complica-
tions.
Non-adherence to treatment protocols is a frequent and
persistent problem in hospitalized IVDU [12]. Therefore,
there may be a perception among health care workers that
IVDU will be less willing to consent to or follow a specific
antibiotic therapy. Such a perception might lead them to
prescribe a less than optimum treatment program because
the preferred protocol would be difficult for the patient to
follow correctly.
Psychiatric co-morbidities in IVDU are reported in up to
30% of IVDU and are recognized as risk factors for needle-
sharing, more frequent sex for money or gifts and being
raped [13], all of which can lead to infection. Patients
with psychiatric diseases are known to have a limited
capacity to consent to proposed interventions and are
consequently more likely to refuse treatment [14]. Psychi-
atric disease as well as intravenous drug use are known
risk factors for patients leaving the hospital against medi-
cal advice and for not adhering to treatment protocols
[15].
Data is still scarce about success rates for treatment of
infectious disease in IVDU in a hospital setting, including
the extent of non-compliant patient behavior and its
impact on the efficacy of treatment and patient outcomes.
Therefore, the goal of the present study was to analyze the
appropriateness of treatment protocols, compliance with
treatment by patients, and the outcomes of therapy in
IVDU who were hospitalized with infectious diseases and
were seen by a specialist in infectious diseases. The
hypothesis was that the appropriateness of treatment pro-
tocols in IVDU was higher than suspected by most physi-
cians and that the outcome of treatment depends on the
appropriateness of treatment and the compliance of the
patients.
Methods
Study design
This was a retrospective study of all IVDU who were hos-
pitalized for treatment of infectious diseases and were
evaluated on demand by the infectious disease service
over six years, January 2001 through December 2006, in
the University Hospital Basel in Switzerland, a 780-bed
primary and tertiary care center with approximately
27,000 admissions annually.
One single investigator extracted the following data from
hospital charts as well as from the separate medical charts
of the infectious disease specialists who were consulted:
Name; gender; date of birth; date of admission; duration
of hospitalization; date of infectious disease specialist
consultations; duration of illicit drug use and which sub-
stances used; participation in an opioid maintenance pro-
gram; main diagnosis and co morbidities; body mass
index; infectious diseases diagnosis; main pathogen; addi-
tional pathogens; antibiotics, doses, application forms
and durations of treatment; complications (i.e. acute renal
failure, adult respiratory distress syndrome, disseminated
intravasal coagulation, septic shock); admission to inten-
sive care unit (ICU) and days on ICU; fatalities and rea-
sons of death; fever, c-reactive protein and leucocytes at
time of admission and time of discharge; time to defe-
verescence; readmission and reason for readmission. The
data was entered in a database (SPSS 14, SPSS Inc., Chi-
cago US), controlled by a second investigator and checked
for plausibility during analysis of the dataset by another
two independent reviewers.
Treatment protocols were evaluated with respect to their
appropriateness for treating the diagnosed infection.
Where treatment programs deviated from accepted stand-
ards, the reason for the use of an alternative program was
noted. Participation in any program of heroin or metha-
done substitution administered by a public organization
was considered participation in an opioid maintenance
program.
A patient's behavior was considered to be non-compliant
if it was disruptive and violated hospital rules according to
the charts, i.e., if the patient did not comply with diagnos-
tic measures or adhere to therapeutic measures, left the
hospital against medical advice, continued intravenous
drug use during hospitalization, smoked in the room, or
assaulted hospital staff.
The study was approved by the Ethics Committee of the
Cantons Basel-Stadt and Basel-Land (EKBB).
Outcome parameters
The outcome parameters were the appropriateness of the
prescribed therapy (the choice of treatment and the dura-BMC Infectious Diseases 2008, 8:42 http://www.biomedcentral.com/1471-2334/8/42
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tion of treatment with respect to standard guidelines for
treating specific infectious diseases), the readmission rate
(overall rate and the rate due to relapse), in-hospital mor-
tality (both infectious-disease related and non-infectious-
disease related), and outpatient mortality (death registries
for the Canton Basel-Stadt).
Relapse was defined as infection by the same microorgan-
ism(s) responsible for the initial infection at the same site
within 30 days after the patient was discharged from the
hospital. For osteomyelitis, the time limit for relapse was
extended to twelve months.
Standards of diagnosis
Briefly, the most important definitions were: skin and soft
tissue infections according to the practice guidelines of the
Infectious Diseases Society of America [16]; pneumonia
according to the European guidelines [17]; endocarditis
according to the Dukes criteria [18]; septic thrombosis
was defined by positive blood cultures and the detection
of a thrombus in imaging [19,20], Finally, sepsis was
defined by an infection and two or more SIRS (systemic
inflammatory response syndrome) criteria [21]. Other
diagnoses of infectious diseases were according to the
Centers for Disease Control and Prevention (CDC) guide-
lines [22].
Major psychiatric disease, defined as major depression,
schizophrenia, or personality disorders, was noted if men-
tioned in the final medical report as assed by a board cer-
tified psychiatrist.
Complications were defined as non-compliant patient
behavior, renal failure, septic shock, or admission to the
intensive care unit (ICU) during hospitalization.
Standards of treatment
The appropriateness of the prescribed therapy was evalu-
ated according to written internal guidelines of the infec-
tious diseases division, which are closely adapted from
international guidelines (The Sanford Guide To Antimi-
crobial Therapy 2007, [16,17,23,24]). Antibiotic therapy
for septic thrombosis is based on expert opinions [23]. In
our study, therapy for septic thrombosis was defined as
adequate if a minimum duration of four weeks of treat-
ment was planned and the antibiotic was given intrave-
nously for the first 2 weeks [20] according to the
guidelines for treating right heart endocarditis [24,25].
The appropriateness of treatment was analyzed by at least
two investigators, which were not informed about the out-
come of the cases at time of analysis. If there was no agree-
ment, a third investigator was consulted. Whenever a
pathogen was isolated, antibiotic susceptibility testing
was considered for treatment. Our laboratories are work-
ing according to Clinical and Laboratory Standards Insti-
tute (CLSI) guidelines.
Statistical analysis
A multiple logistic regression model was used to describe
the dependence of patient compliance and in-hospital
mortality on covariates, which were chosen according to
clinical concerns. Adjustment for multiple hospitaliza-
tions of individual patients was made by using a general-
ized estimating equation (GEE) approach. Parameters
were first estimated by using ordinary logistic regression,
ignoring correlations between different hospitalization
periods for a single patient (under "working independ-
ence"). Standard errors were then adjusted for repeat hos-
pitalizations by using a robust sandwich estimator. The
same statistical approach was used for univariate analyses.
Results are given as odds ratio (OR) and 95% confidence
interval (CI).
Results
Study population
During six years, between January 2001 and December
2006, there were 2002 hospitalizations of IVDU (Figure
1). In 420 of these hospitalizations, a specialist in infec-
tious diseases was consulted. Of these 420 cases, 76
(18.1%) were excluded from the study. Demographic data
and laboratory results for the 344 hospitalizations of 216
patients are summarized in Table 1. Although the major-
ity of IVDU (93.7%) were enrolled in an opioid mainte-
nance program, 98.4% also used illicit drugs in addition
to their maintenance doses. The patients in this study
population suffered from diverse co-morbidities and mal-
nutrition as indicated by the rather low body mass index.
The median time to the first consultation by an infectious
diseases specialist was 2 days (range 0–92 days). In
median, two consultations (range 1–10) were performed
per patient.
Diseases and pathogens
The distribution of infectious diseases that were diag-
nosed in this population, the number of infections per
hospitalization of a patient, the number of surgical inter-
ventions, and the comorbidities that were observed in the
patients are summarized in Table 2. The most frequent
diagnoses were skin and soft tissue infections followed by
pneumonia and endocarditis. A high number of septic
thromboses was diagnosed (n = 36, 10.5%). In addition,
23 non-septic thromboses of the deep venous system were
diagnosed. Sepsis or severe sepsis due to different infec-
tions was documented in 35.5% (n = 122) cases, with no
obvious clinical focus in 7.6% (n = 26). Of the 'various
infections' listed in Table 1 (n = 75, 21.8%), the most fre-
quently encountered were upper respiratory tract infec-
tions (n = 12), infections by Candida species (n = 10),BMC Infectious Diseases 2008, 8:42 http://www.biomedcentral.com/1471-2334/8/42
Page 4 of 10
(page number not for citation purposes)
urinary tract infections (n = 10), abdominal infections (n
= 6), tuberculosis (n = 5) and sinusitis (n = 4). Eighty-six
(25%) of the cases were characterized by two or more
simultaneous infections. Viral co-infections, i.e., hepatitis
C, HIV, and chronic hepatitis B, were common as comor-
bidities. Like IVDU in an earlier study [11,26], close to
80% of the patients in this study were positive for hepati-
tis C.
Overall, a pathogen could be isolated in 78.8% of the
cases (Table 3). The percentage of microbiologically doc-
umented infections was 100% for bacterial endocarditis
and septic thrombosis, 96% for bone and joint infections,
85.7% for primary sepsis without focus, 77.7% for skin
and soft tissue infections, and 72% for pneumonia. The
percentage of microbiologically documented infections
for all other types of infections together was 62.3%.
S. aureus was the most frequently isolated pathogen, fol-
lowed by beta-hemolytic and viridans streptococci (Table
3). S.aureus was the most frequent pathogen isolated in all
categories of infections: endocarditis (76% of cases with a
primary pathogen identified), bone and joint infections
(58%), primary sepsis (57%), septic thrombosis (56%),
skin and soft tissue infections (45%), pneumonia (35%)
and in other infections (35%). Polymicrobial infections
were observed in 18.6% of cases.
Therapy and outcome
A beta-lactam antibiotic, most frequently amoxicilline/
clavulanate, was used for treatment in 84.9% of the cases
(Table 3). The median duration of intravenous and oral
antibiotic therapy was 12 days (range 0–117 days) and 1
day (range 0–36 days), respectively.
Treatment according to standard guidelines was possible
in 270 (78.5%) of the 344 hospitalizations. A best alter-
native therapy was prescribed as recommended by an
infectious disease specialist for non-compliant patients in
39 (11.3%) cases. Therapy that was not according to an
infectious disease specialist advice was prescribed in 35
(10.2%) cases (Figure 1).
For some infections, e.g., for skin and soft tissue infec-
tions, sepsis, or pneumonia, 47.1% of the cases were
scheduled for additional outpatient therapy after an ade-
quate or best alternative in-hospital course of treatment
(Table 4). In 12.2% of the hospitalizations, patients were
discharged against medical advice either with or without
therapy.
Complications occurred in 153 hospitalizations (44.5%).
Complications noted were acute renal failure (8.4%) and
septic shock (3.2%). In 21.5% of the hospitalizations, the
patients were admitted to the ICU (median length of ICU
stay = 3 days). The presence of pneumonia or endocarditis
most often led to ICU admission–36% of all cases of
pneumonia and 29.6% of all cases of endocarditis. Non-
compliant patient behavior was the most frequent com-
plication (19.8%), and a multiple logistic regression anal-
ysis (Table 5) revealed a significant association of non-
compliance with psychiatric disorders (OR = 2.4, CI 1.1–
5.1, p = 0.03). In hospitalizations of non-compliant
patients, the patient was able to follow the prescribed
therapeutic program in accordance with standard guide-
lines in 27.9% of the cases.
The overall 30-day readmission rate was 13.7% (Table 4).
Among readmitted cases, 27.7% had a relapse (overall
relapse rate 3.8%). The highest relapse rates occurred with
septic thrombosis (5.6%) and endocarditis (3.7%). Both
non-compliant patient behavior (OR = 3.7, CI 1.3–10.8, p
= 0.02) and non-adherence to treatment guidelines (OR =
3.3, CI 1.1–9.7, p = 0.03) were associated with a signifi-
cant increase in the relapse rate in univariate analysis.
Study population and frequency of relapses according to dif- ferent treatment modalities in 344 hospitalizations among  216 IVDU* Figure 1
Study population and frequency of relapses according 
to different treatment modalities in 344 hospitaliza-
tions among 216 IVDU*. IVDU = Intravenous drug users. 
n = Number of hospitalizations. ID = Infectious disease spe-
cialist. Rx = Prescribed treatment. * seen by an ID during a 
period of 5 years. † Not included in study: -Patients who did 
not require antibiotic. -Former IVDU who had stopped using 
narcotics at least two years prior to their admittance to the 
hospital and were not participating in an opioid maintenance 
program ††p = 0.03 (Rx according to guidelines vs. others)
All hospitalizations of 
IVDU 2001-2006 
n = 2002
†Hospitalizations with no     
ID consultation 
n = 1582
Hospitalizations 
ID involved 
n = 420
†Hospitalizations for 
which data was not 
available
n = 12
†Hospitalizations that required 
no antibiotic therapy 
n = 50
†Cessation of narcotics >2 years 
prior to consultation n = 14
Number of hospitalizations for infections in IVDU with 
consultation by ID specialist n = 344
Rx according to 
guidelines         
(ID advice) 
n = 270 (78.5%)
Best alternative Rx in 
non-compliant patients
(ID advice) 
n = 39 (11.3%)
Rx not according to 
guidelines or  
ID advice
n = 35 (10.2%)
Relapses
n = 7/270 (2.6%)
††
Relapses
n = 2/39 (5.1%)
††
Relapses
n = 4/35 (11.4%)
††BMC Infectious Diseases 2008, 8:42 http://www.biomedcentral.com/1471-2334/8/42
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Because of the low number of relapses, no multiple
(adjusted) logistic models were performed.
Overall in-hospital mortality was 6.4% (n = 22, Table 4).
The highest mortality rates were associated with bacterial
endocarditis (13%), pneumonia (12%), and sepsis
(9.6%). The age of the patient was the only independent
risk factors for infection-related, in-hospital mortality
(Table 5). State death record information was available
for 199 (92.1%) of the 216 patients, which allowed the
evaluation of mortality rates after discharge from the hos-
pital (a total of 590 person-years of follow-up). The
Table 1: Patient characteristics of 344 hospitalizations among 216 IVDU*
%
Gender (male/female) (n = 344) 67/33
Participation in opioid maintenance program (information available in n = 270)
In a program = 253 93.7
No program = 17 6.3
median (range)
Age (years) (n = 344) 38 (18–58)
Body mass index (kg/m2) (n = 212) 20.9 (14–40)
Temperature at admission (°C) (n = 328) 38.6 (35.3–42)
C-reactive protein at admission (mg/l) (n = 342) 121.5 (0.7–514)
White blood cell count (× 109/l) (n = 342) 10.9 (0.1–80.4)
Length of hospital stay (days) (n = 344) 17 (1–125)
* seen by an ID during a period of 5 years.
†Data on opioid substitution program participation, body mass index, temperature, white cell count, and C-reactive protein was not available for all 
patients.
IVDU = Intravenous drug user.
n = Total number of hospitalizations for which specific data was available. (Total number of hospitalizations in this study = 344.).
ID = Infectious disease specialist
Table 2: Infectious disease diagnoses and co-morbidities in 344 hospitalizations among 216 IVDU*
n (%)
Types of infectious disease diagnoses†:
Skin and soft tissue infection 129 (37.5)
Pneumonia 75 (21.8)
Endocarditis 54 (15.7)
Bone and joint infections 50 (14.5)
Septic thrombosis 36 (10.5)
Primary sepsis without focus 26 (7.6)
Various infections 75 (21.8)
Number of simultaneous infections:
one infection 258 (75.0)
two infections 70 (20.3)
three or more infections 16 (4.7)
Number of hospitalizations where surgical intervention was required 110 (32.0)
Comorbidities†:
Major psychiatric disease 52 (15.1)
Alcohol addiction 55 (16.0)
Nicotin addiction 265 (77.0)
HIV infection 120 (34.9)
Chronic hepatitis B 47 (13.7)
Hepatitis C 268 (77.9)
Anemia 157 (45.5)
Deep venous thrombosis (non-septic) 23 (6.7)
IVDU = Intravenous drug users.
* seen by an ID during a period of 5 years.
† 447 diagnoses among 344 hospital episodes. During one hospital episode more than one diagnosis and comorbidity can be documentedBMC Infectious Diseases 2008, 8:42 http://www.biomedcentral.com/1471-2334/8/42
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median observation time was 35.6 months (range 1.6–
73.9 months). A total of 49 (24.6%) patients died during
the observation period. Of these 49 patients, 27 (55.1%)
died after discharge from the hospital, 3 of them within
30 days (2 for whom death was possibly infection related,
1 who died of a trauma). The remaining 24 deaths
occurred more than 30 days after the last date of discharge
(median 232 days).
There was no significant difference in non-compliant
behavior, relapse- or readmission rate between HIV-
infected and HIV-negative patients. The association
between infection-related deaths and HIV status during
hospitalization was non-significant (OR = 1.9, CI 0.8–4.9,
p = 0.161). Overall in hospital mortality (OR = 2.4, CI
1.0–5.6, p = 0.06) and mortality in the follow up period
(OR = 2.4, CI 1.3–4.4, p = 0.006) was increased for epi-
sodes with HIV-infected patients.
Discussion
This study investigating 344 hospitalizations in 216 IVDU
demonstrates that the vast majority of infectious disease
episodes in these patients can be treated successfully by
following international guidelines or protocols adapted
from these standard guidelines.
Treatment according to guidelines was completed in 78%
of hospitalizations, and treatment with a best alternative
regimen recommended by a specialist in infectious dis-
eases was possible in an additional 11% of patients who
had been identified as non-compliant (Figure 1). Hence,
even complex and prolonged intravenous antibiotic treat-
ment can be administered successfully in almost 90% of
IVDU. Prescription of alternative treatment programs and
non-adherence by patients were associated with a twofold
and fourfold increase in the relapse rate, respectively.
However, when the recommendations of an infectious
disease specialist were followed, relapse occurred in only
2.6% of the cases (Figure 1). Physicians should be aware
that deviating from recommended protocols is associated
with a higher rate of treatment failure and relapse. Making
compromises in treatment strategies cannot be justified
on the basis of a belief that a patient may not adhere to the
prescribed program. In an earlier study of HIV-infected
patients, it was demonstrated that IVDU also are at risk of
receiving inadequate treatment for HIV, in part because
physicians did not follow the treatment programs that
were recommended by infectious disease specialists [27].
The extent of adherence to recommended treatment pro-
grams for infections in IVDU and its relationship to treat-
ment outcome had not been analyzed prior to this study.
Self-reported, non-adherence to therapy is a problem for
IVDU who are being treated for infectious diseases, just as
it is for IVDU who are receiving antiretroviral therapy
[28]. Therefore, a patient's adherence to a program of tak-
ing oral antibiotics after the patient has been discharged
from the hospital cannot be taken for granted. The high
rate (>90%) of IVDU who were participating in a struc-
tured opioid maintenance program may partially explain
the high rate of adherence to treatment programs by
patients in the study population, even though almost all
patients reported using illicit drugs in addition to their
official maintenance drug dose, which points to their
severe addiction.
Major psychiatric disorders were associated with a
reduced adherence in our study, which confirms other
reports in the literature that describe the more risky
behaviors encountered in these patients [13]. Gender, age,
alcohol addiction, and HIV infection had no significant
impact on patient compliance in a multivariate analysis
(Table 5).
The mortality rate for IVDU is known to be greater than
that of the general population [29]. In our study popula-
tion, in-hospital mortality (6.4%) was rather low (Table
Table 3: Pathogens identified and antibiotic therapies used in 344 
hospitalizations among 216 IVDU*
n (%)
Pathogens
Staphylococcus aureus 131‡ (38.1)
Beta-hemolytic streptococci 42 (12.2)
Viridans streptococci 30 (8.7)
Enterobacteriaceae 17 (4.9)
Streptococcus pneumoniae 14 (4.1)
Pseudomonas aeruginosa 10 (2.9)
Coagulase-negative staphylococci 6 (1.7)
Mycobacteria spp. 6 (1.7)
Other pathogens 15 (4.4)
Polymicrobial infections 64 (18.6)
No pathogen identified 73 (21.2)
Therapy†
Beta-lactams 292 (84.9)
Amoxicilline/Clavulanate 129 (37.5)
Penicilline 54 (15.7)
Flucloxacilline 48 (14.0)
Cephalosporines 33 (9.6)
Piperacilline/Tazobactam 18 (5.2)
Carbapenemes 10 (2.9)
Non-beta-lactams
Aminoglycosides (used in combination) 10 (2.9)
Fluoroquinolones 8 (2.3)
Antituberculosis drugs 6 (1.7)
Others 28 (8.1)
* seen by an ID during a period of 5 years.
† Antibiotic prescribed for the longest period intravenously during 
one hospitalization.
‡ Two of 131 (1.53%) S.aureus infections were due to methicillin-
resistant S.aureus (MRSA).BMC Infectious Diseases 2008, 8:42 http://www.biomedcentral.com/1471-2334/8/42
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4). Most deaths during the study occurred more than 30
days after discharge from the hospital and were not
related to prior hospitalization for treatment of infectious
disease. Similar observations were made in a longitudinal
study among opioid addicts [29]. The only independent
risk factor for in-hospital death in this study was older age
(Table 5). In-hospital deaths of IVDU were primarily due
to uncontrolled active infections despite their receiving
adequate therapy for the infections according to standard
guidelines. The highest mortality rate was observed in
patients with bacterial endocarditis (13%). This rate is
comparable to infection-related, in-hospital mortality
rates attributable to endocarditis among in hospital
patients who are not addicts (14%; in-house, unpublished
data). The data includes mortality due to both right-sided
and left-sided and staphylococcal and streptococcal endo-
carditis. Although IVDU may not seek medical treatment
until late in the course of an infectious disease and have a
Table 4: Discharge data for 344 hospitalizations among 216 IVDU* for treatment of infectious diseases
n (%)
Discharge with oral antibiotics after adequate or best alternative therapy 162 (47.1)
Discharge without antibiotics after adequate or best alternative therapy 117 (34.0)
Discharge against medical advice, with oral antibiotics 29 (8.4)
Discharge against medical advice, without antibiotic therapy 13 (3.8)
Discharge without available follow-up data for antibiotic therapy 1 (0.3)
In-hospital deaths† 22 (6.4)
Total 344 (100)
Readmissions
< 30 days with relapse of original infection 13 (3.8)
with infection but not relapse of original infection 19 (5.5)
with no infection 15 (4.4)
30–90 days 53 (15.4)
> 90 days 100 (29.1)
Deaths overall (determined from state records for n = 199 patients) 49 (24.6)
After discharge from hospital: not related to treated infection 27 (13.6)
In-hospital (of cases):
infection related 18 (5.2)
not infection related 4 (1.2)
IVDU = Intravenous drug users.
* seen by an ID during a period of 5 years.
† Described in detail in the lower part of the table.
Table 5: Risk factors associated with patient non-compliance and infection-related mortality (multiple logistic regression analysis) of 
344 hospitalizations among 216 IVDU*
Risk factors for patient's non-compliance OR (95% CI) p-value
Male gender 1.2 (0.6–2.2) 0.60
Age (per 10 years older) 0.8 (0.5–1.2) 0.26
Alcohol addiction 0.8 (0.4–1.7) 0.55
Psychiatric disorders 2.4 (1.1–5.1) 0.03†
HIV infection 0.7 (0.3–1.3) 0.24
Risk factors for infection-related mortality OR (95% CI) p-value
Number of infections 1.4 (0.7–2.9) 0.32
Age (per 10 years older) 2.0 (1.0–3.8) 0.04†
Male gender 1.0 (0.4–2.6) 0.93
Number of comorbidities 1.0 (0.8–1.3) 0.95
* seen by an ID during a period of 5 years.
† Statistical significance (p < 0.05).BMC Infectious Diseases 2008, 8:42 http://www.biomedcentral.com/1471-2334/8/42
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greater number of co-morbidities and complications, they
tend to be younger and have a predominant involvement
of the tricuspid valve [30]. Both factors contribute to a
lower mortality compared to the 20–25% mortality in sta-
phylococcal endocarditis of the left heart [24,31-33].
Our study corroborates results from earlier studies
[1,2,34] that show that skin and soft tissue infections are
the most frequently occurring infections in IVDU (Table
2). In about half the cases of skin and soft tissue infection,
surgical intervention was implemented in addition to
antibiotic therapy. The duration of intravenous antibiotic
therapy is quite short for skin and soft tissue infections,
which may partly explain the high rate of adherence to our
guidelines.
The majority (36 of 59) of deep venous thromboses in
IVDU was septic, constituting 10.5% of hospitalizations.
These results emphasize the importance of screening for
signs and symptoms of deep venous thrombosis in IVDU.
In almost 80% of the hospitalizations, the causative path-
ogen for the infection could be identified. The predomi-
nance of S. aureus and streptococci (Table 3) confirms
earlier results [5,6,31,35-38]. Methicillin-resistant S.
aureus (MRSA) may lead to outbreaks of infection among
IVDU [39,40], although in our study, MRSA was isolated
to only two cases–both in the same patient, which con-
firms the low prevalence of MRSA in our region [41,42].
Amoxicilline/clavulanate was the antibiotic used most fre-
quently to treat infections (Table 3), which is comparable
to results in other studies, e.g., a similar study conducted
in the emergency department of the University Hospital
Basel studying the general patient population [43].
The main limitation of this study is its retrospective char-
acter. The source of our data was restricted to hospital
medical records and the detailed records of the specialists
in the infectious diseases department. A second limitation
is that detailed information about the duration of drug
addiction in patients was missing in most cases. There-
fore, we were not able to substantiate the impression that
the risk for hospitalization due to infections increased
with the number of years of addiction. Nevertheless, the
age of our study population is rather high (median 38
years, mean 37 years) in comparison with the mean age of
IVDU in a Swiss heroin maintenance program (mean
20.2–27 years, depending on the addictive drug that was
being used, 2001) [44]. Hence, younger patients were
underrepresented in hospitalized IVDU in our study.
Only in part, this can be explained by the increasing mean
age of IVDU over time as shown in the US recently [45]. A
third limitation is the fact that co-morbidities could not
be investigated in detail, for example, the fact that there
was no reference to co-morbidity in a patient's final med-
ical report does not completely exclude the possibility of
co-morbidity having existed and we were not able to
standardize the assessment of non-compliant behavior.
As fourth limitation, we analyzed only hospitalization
seen by infectious disease specialists and a generalization
to all IVDU hospitalizations may be limited. Nevertheless,
we assume that we were consulted for the more difficult
situations rather enforcing the good appropriateness.
The strength of this study was the high number of hospi-
talizations that were investigated in a population of
IVDU. Although this study was a retrospective investiga-
tion, we were able to extract significant information from
the general medical charts and from the detailed reports of
the infectious disease specialists by using a sophisticated
case report form that included precise definitions of dif-
ferent infectious diseases. Also, our outcomes were vali-
dated by the state death records, which confirmed the
favorable outcome in most patients.
Conclusion
Appropriate antibiotic therapy in hospitalized IVDU is
generally practicable and successful. In a minority of
cases, alternative treatments may be indicated, although
they are associated with a higher risk of failure. Compli-
cated disease courses and readmissions are common in
IVDU; but in this study, only a small percentage of
readmissions were due to relapse. Overall mortality in this
population of IVDU is high, but it does not appear to be
related to prior hospitalizations for infectious disease.
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